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There are fewer multiple sclerosis (MS) 
patients in wheelchairs than ever before 
in South Africa (SA), mainly owing to the 
advent of interferon drugs over the past 
decade and better second-line drugs over 
the past 3 years, says Prof. Girish Modi, 
Head of Neurology at the University of 
the Witwatersrand. He was responding 
to claims last month by the Biokinetics 
Association of South Africa (BASA) that 
physical activity helps manage symptoms 
and prevent compli cations and can 
perhaps even slow progression of MS.
Last month (May) marked International 
Multiple Sclerosis Awareness Month, 
and Izindaba was testing assertions by 
BASA that movement and exercise were 
therapeutic (contrary to decades-old 
‘wisdom’ that exercise worsens MS). Modi, 
who is also Head of Neurology at Charlotte 
Maxeke Hospital in Johannesburg, said a 
sense of wellbeing had been shown to have 
‘some relevance’ in autoimmune diseases, 
‘so a healthy lifestyle is a good thing, but 
there’s no scientific evidence that exercise 
will reduce attacks or control the disease’. 
Areta Potgieter, an executive member of 
BASA and a practising biokineticist, had 
claimed that one of the most ‘profound’ 
recent changes in MS treatment and 
management related to exercise, with 
fatigue affecting 75 - 90% of all MS 
patients, many of whom avoided physical 
activity to try to reduce the symptoms of 
fatigue.
However, Modi said the most profound 
change was in pharmaceuticals, with inter-
feron or the similar Copaxone becoming 
far more widely available in the private 
sector over the past decade. Second-line 
drugs such as Tysabri and Gilenya now 
helped modify the immune response and 
avoid relapse, though they carried some 
very significant risk. Evidence following 
the use of interferon ‘clearly shows fewer 
people now in wheelchairs’, he said. 
Medical aids had ‘come to the party with 
interferon’, and most MS sufferers in the 
private sector were now on it. Any patient 
who had had two or more MS attacks 
within the past 12 months should be on 
interferon, which cost ZAR7 000 - ZAR9 000 
per month. Only ‘a handful’ of patients were 
on it in the public sector because of cost 
considerations. There are an estimated 5  000 
known MS sufferers in SA.
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Prof. Girish Modi, Head of Neurology at the 
University of the Witwatersrand.
Multiple sclerosis is a chronic, typically 
progressive disease that causes demy-
elination (disruption of the myelin that 
insulates and protects nerve cells) of spi-
nal nerve and brain cells. The significant 
risk in the second-line drugs that Modi 
refers to is a condition known as pro-
gressive multifocal leucoencephalopathy 
(PML), caused by activation of what’s 
called the JC virus in the brain – which 
can be fatal.
Medical aids had ‘come to the 
party with interferon’, and most 
MS sufferers in the private sector 
were now on it. Any patient who 
had had two or more MS attacks 
within the past 12 months 
should be on interferon, which 
cost ZAR7 000 - ZAR9 000 per 
month.
